上海美迪西生物医药股份有限公司 股东提前终止减持计划暨减持股份 结果公告

Core Viewpoint - The major shareholder of Shanghai Medicilon Inc., Chen Guoxing, has decided to terminate his share reduction plan early, maintaining his current holdings due to confidence in the company's stable development and changes in personal financial needs [3][6]. Shareholder Holdings - Before the reduction plan, Chen Guoxing held 4,875,154 shares, accounting for 3.63% of the total share capital, while his concerted action partner, Lin Changqing, held a total of 8,806,324 shares, representing 6.55% of the total share capital [2][8]. Reduction Plan Implementation Results - On November 20, 2025, Chen Guoxing announced a plan to reduce his holdings by up to 2,200,000 shares (1.64% of total share capital) within three months, but as of the announcement date, he had not executed any reductions and still held 4,875,154 shares [3][6]. - The decision to terminate the reduction plan was based on Chen's confidence in the company's ongoing stability and changes in his financial situation [3][6]. Future Shareholding Intentions - Following the completion of the reduction plan, Lin Changqing intends to continue holding his shares and will consider reducing his holdings based on personal development needs while adhering to relevant laws and commitments [9][10].